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Letters to the Editor
Should Genotypic Testing Be Done on All Phenotypically Vancomycin-Resistant
Enterococci Detected in Hospitals?
We wish to report the detection of vanA and vanC genes in
Enterococcus gallinarum, because the detection of vanA genes
in a motile enterococcus has potentially important implications
for infection control practice in hospitals.
Since 1986, vancomycin-resistant E. faecium and E. faecalis
have become major nosocomial pathogens in the United States
and in several European countries (1, 7). Two principal phe-
notypes of acquired vancomycin resistance have been de-
scribed, VanA and VanB, encoded by two distinct gene clus-
ters, the vanA and vanB clusters (5). Both genes are mobile on
either plasmids or transposons. The vanA genes typically con-
fer high-level resistance to vancomycin (MIC $ 128 mg/liter)
and teicoplanin (MIC $ 16 mg/liter), while vanB genes typi-
cally result in moderate to high-level resistance to vancomycin
(MIC 5 16 to 64 mg/liter). However, vanA and vanB genotypes
associated with different resistance phenotypes have been re-
ported. The motile enterococci, E. gallinarum, E. casseliflavus,
and E. flavescens, have low-level intrinsic vancomycin resis-
tance (MIC 5 4 to 16 mg/liter) due to the vanC-1, vanC-2, and
vanC-3 genes, respectively. VanA- and VanB-type resistance in
the motile enterococci has been reported on only a few occa-
sions, and as far as we are aware not in Australia (2, 8).
Recently, an E. gallinarum strain (WBG 9213) isolated from
a chicken-processing plant was found to have both vanA and
vanC genes. This isolate was identified by the Facklam and
Collins identification scheme (3). Differentiation between E.
gallinarum and E. casseliflavus was based on the lack of pig-
ment production on 5% sheep blood agar after 24 h of incu-
bation. Antimicrobial susceptibility testing was performed by
Kirby-Bauer disk diffusion and E test (AB Biodisk, Sweden)
methods by using Mueller-Hinton agar supplemented with 5%
horse blood, and by using the Vitek GPS-TB card (bio-
Mérieux-Vitek). The interpretative criteria of the National
Committee for Clinical Laboratory Standards (NCCLS) were
used for determining susceptibility of the isolates (6). WBG
9213 grew on the NCCLS vancomycin resistance screening test
plate, brain heart infusion agar supplemented with 6 mg of
vancomycin per liter.
The van genes were detected by PCR using the oligonucle-
otide primers for vanA, vanB, vanC-1, and vanC-2 genes as
reported by Free and Sahm (4). The target gene and product
size for each of the control strains are described in Fig. 1. vanA
and vanB amplifications were performed as a multiplex reac-
tion. vanC-1 and vanC-2 amplifications were performed sepa-
rately.
Both the 822-bp (vanC-1) and 783-bp (vanA) PCR products
were detected in WBG 9213 (Fig. 1). This isolate had a VanA
phenotype. MICs of vancomycin and teicoplanin as deter-
mined by the E test were $256 and 32 mg/liter, respectively.
Vancomycin resistance was confirmed by Kirby-Bauer disk dif-
fusion (no zone detected) and the Vitek GPS-TB card ($32
mg/liter).
The emergence of acquired and transferable high-level
vancomycin resistance in the motile enterococci is of great
potential clinical and infection control significance. En-
terococci with VanA- or VanB-type vancomycin resistance
encoded by vanA and vanB gene clusters, respectively, are
a major cause of nosocomial infections in some hospitals
in the United States and Europe. Whenever such a strain
is detected in a hospital, strict infection control proce-
dures are applied to prevent transmission to other pa-
tients. However, motile enterococci with their intrinsic
VanC-type low-level vancomycin resistance have not re-
quired special infection control measures. This policy may
no longer be adequate. When vancomycin resistance is de-
tected by phenotypic methods in enterococci other than E.
faecium and E. faecalis, it can no longer be assumed that
such isolates are not carrying mobile plasmids or trans-
posons encoding high-level vancomycin resistance. PCR as-
says need to be done to ensure that these enterococci are
not carrying vanA or vanB genes in addition to vanC genes.
FIG. 1. Agarose gel electrophoresis of vanA, vanB, vanC-1, and vanC-2 PCR
products. (A) Multiplex vanA and vanB gene PCR (lanes 2 to 7) and vanC-1 gene
PCR (lanes 9 to 14). Lanes: 1 and 8, Amresco PCR DNA marker; 2, E. faecalis
ATCC 51299 vanB, 297 bp (product size, 297 bp); 3, E. faecium wild strain vanA,
783 bp (product size, 783 bp); 4, E. gallinarum NCTC 11428 vanC-1, 822 bp (no
product detected); 5, E. casseliflavus ATCC 25788 vanC-2, 439 bp (no product
detected); 6, WBG 9213 (product size, 783 bp); 7, water control; 9, E. faecalis
ATCC 51299 vanB, 297 bp (no product detected); 10, E. faecium wild strain
vanA, 783 bp (no product detected); 11, E. gallinarum NCTC 11428 vanC-1, 822
bp (product size, 822 bp); 12, E. casseliflavus ATCC 25788 vanC-2, 439 bp (no
product detected); 13, WBG 9213 (product size, 822 bp); 14, water control. (B)
vanC-2 gene PCR. Lanes: 1, Amresco PCR DNA marker; 2, E. faecalis ATCC
51299 vanB, 297 bp (no product detected); 3, E. faecium wild strain vanA, 783 bp
(no product detected); 4, E. gallinarum NCTC 11428 vanC-1, 822 bp (no product
detected); 5, E. casseliflavus ATCC 25788 vanC-2, 439 bp (product size, 439 bp);
6, WBG 9213 (no product detected); 7, water control.
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We now recommend that genotypic testing be routinely per-
formed on all clinical isolates of vancomycin-resistant en-
terococci.
VanA phenotype resistance is often mediated by self-trans-
ferable plasmids that have acquired Tn516-related transposons
that carry the vanA gene cluster. Plasmid DNA studies are
being performed on the isolate described here and will be the
subject of a further report.
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